References
[1] McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J 2006;26:154.
[2] Cornejo CM, Haun P, English III J, et al. Immune checkpoint inhibitors and the development of granulomatous reactions. J Am Acad Dermatol 2019;81(5):1165-75.
[3] Esfahani K, Roudaia L, Buhlaiga N, et al. A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol 2020;27(S2).
[4] Dempke WC, Fenchel K, Uciechowski P, Dale SP. Second-and third-generation drugs for immuno-oncology treatment—the more the better?. Eur J Cancer 2017;74:55-72.
[5] Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol 2012;23(S8):viii6-9.
[6] Adams JL, Smothers J, Srinivasan R et al. Big opportunities for small molecules in immuno-oncology Nat Rev Drug Discov 2015;14(9):603-22.
[7] Hoos A, Britten CM. The immuno-oncology framework: Enabling a new era of cancer therapy. Oncoimmunology 2012 May 1;1(3):334-9.
[8] Bagnyukova TV, Serebriiskii IG, Zhou Y, et al. Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?. Cancer Biol Ther 2010 Nov 1;10(9):839-53.
[9] Baskar R, Dai J, Wenlong N, et al. Biological response of cancer cells to radiation treatment. Front Mol Biosci 2014 Nov 17;1:24.
[10] Kaufman HL, Atkins MB, Subedi P, et al. The promise of Immuno-oncology: implications for defining the value of cancer treatment. J Immunother Cancer 2019;7(1):129.
[11] Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol 2018 Feb;15(2):81.
[12] Harris SJ, Brown J, Lopez J, et al. Immuno-oncology combinations: raising the tail of the survival curve. Cancer Biol Med 2016;13(2):171.